Calcium Chloride 0.2 Mg/ml / Glucose 50 Mg/ml / K+ Chloride 1.79 Mg/ml / Nacl 6 Mg/ml / Sodium Lactate 3.1 Mg/ml Injectable Solution
- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 5 WARNINGS AND PRECAUTIONS
- 6 ADVERSE REACTIONS
- 7 DRUG INTERACTIONS
- 8 USE IN SPECIFIC POPULATIONS
- 10 OVERDOSAGE
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
- 13 NONCLINICAL TOXICOLOGY
- 16 HOW SUPPLIED/STORAGE AND HANDLING
1 INDICATIONS AND USAGE
Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is indicated for use as a source of water, electrolytes, and calories or as an alkalinizing agent in adults and pediatric patients.
2 DOSAGE AND ADMINISTRATION
2.1 Dosage Considerations
-
Use a non-vented infusion set or close the vent on a vented set. -
Use a dedicated line without any connections (do not connect flexible containers in series). -
The use of pressure infusion is not recommended as a method to increase flow rates. However, if pressure infusion is required, ensure that any air within the bag is fully evacuated prior to initiation of infusion. -
If using a pumping device to administer Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection, turn off the pump before the container is empty.
-
Tear overwrap downside at slit and remove solution container. -
Visually inspect the container. -
If the outlet port protector is damaged, detached, or not present, discard container as solution path sterility may be impaired. -
Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.
-
-
Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. -
If supplemental medication is desired, follow directions below [see Dosage and Administration (2.3) ] .
-
Suspend container from eyelet support. -
Remove protector from outlet port at bottom of container. -
Attach administration set according to its accompanying directions.
2.3 Important Administration Instructions
-
Use a peripheral vein to administer Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection if the final dextrose concentration is 5% or less, and the osmolarity is less than 900 mOsm/L. -
Consider using a central vein to administer hypertonic solutions with osmolarity of 900 mOsm/L or more to avoid venous irritation [see Warnings and Precautions (5.7) ].
-
Prepare medication site. -
Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. -
Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.
-
Close clamp on the set. -
Prepare medication site. -
Using syringe with19 to 22 gauge needle, puncture resealable medication port and inject. -
Remove container from IV pole and/or turn to an upright position. -
Evacuate both ports by squeezing them while container is in the upright position. -
Mix solution and medication thoroughly. -
Return container to in use position and continue administration.
2.4 Drug Incompatibilities
3 DOSAGE FORMS AND STRENGTHS
Injection: Potassium Chloride (20 mEq) in Lactated Ringer’s and Dextrose (5%) Injection, USP as a clear, sterile, and nonpyrogenic solution packaged in a single-dose VIAFLEX plastic container: 1,000 mL.
4 CONTRAINDICATIONS
-
Neonates (28 days of age or younger) who are receiving concomitant treatment with ceftriaxone, even if separate infusion lines are used, due to the risk of fatal ceftriaxone-calcium salt precipitation in the neonate’s bloodstream [see Warnings and Precautions (5.1) andSpecific Populations (8.4) ]. -
Patients with known hypersensitivity to any of the components of Potassium Chloride in Lactated Ringer’s solution and Dextrose (5%) Injection [see Warnings and Precautions (5.3) ]. -
Patients with clinically significant hyperkalemia [see Warnings and Precautions (5.4) ]. -
Patients with clinically significant hyperglycemia [see Warnings and Precautions (5.7) ].
5 WARNINGS AND PRECAUTIONS
5.1 Serious Risk with Concomitant Use with Ceftriaxone
5.2 Air Embolism
5.3 Hypersensitivity Reactions
5.4 Potassium Imbalances
Potassium-containing solutions, including Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection, may increase the risk of hyperkalemia. This risk is increased in patients predisposed to hyperkalemia including those with severe renal impairment, acute dehydration, extensive tissue injury or burns, heart failure, or in those using concomitant drugs that are associated with hyperkalemia.
5.5 Hyponatremia
5.6 Neonatal Hypoglycemia
5.7 Hyperglycemia and Hyperosmolar Hyperglycemic State
5.8 Hypercalcemia
5.9 Fluid Overload
5.10 Acid/Base Imbalances
5.11 Interference of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection with Interpretation of Serum Lactate Levels in Patients with Severe Metabolic Acidosis
6 ADVERSE REACTIONS
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
-
Serious Risk with Concomitant Use with Ceftriaxone [see
Warnings and Precautions (5.1) ] -
Air Embolism [see
Warnings and Precautions (5.2) ] -
Hypersensitivity Reactions [see
Warnings and Precautions (5.3) ] -
Potassium Imbalances [see
Warnings and Precautions (5.4) ] -
Hyponatremia [see
Warnings and Precautions (5.5) ] -
Neonatal Hypoglycemia [see
Warnings and Precautions (5.6) ] -
Hyperglycemia and Hyperosmolar Hyperglycemic State [see
Warnings and Precautions (5.7) ] -
Hypercalcemia [see
Warnings and Precautions (5.8) ] -
Fluid Overload [see
Warnings and Precautions (5.9) ] -
Acid/Base Imbalances [see
Warnings and Precautions (5.10) ]
The following adverse reactions have been identified during postapproval use of Lactated Ringer’s products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:
-
General Disorders and Administration Site Conditions:
Phlebitis, extravasation, infusion site inflammation, infusion site swelling, infusion site rash, infusion site pruritus, infusion site erythema, infusion site pain, infusion site burning, and infusion site hypoaesthesia. -
Hypersensitivity Reactions and Infusion Reactions:
Angioedema, chest pain/discomfort, bradycardia or tachycardia, hypotension, respiratory distress, bronchospasm, dyspnea, cough, urticaria, rash, pruritus, erythema, flushing, throat irritation, paresthesia, oral hypoesthesia, dysgeusia, nausea, anxiety, pyrexia, and headache, laryngeal edema, sneezing, injection site infection. -
Metabolism and Nutrition Disorders:
Hyperkalemia, hyponatremia, and hypervolemia. -
Nervous System Disorders:
Hyponatremic encephalopathy.
7 DRUG INTERACTIONS
7.1 Drugs that Affect Electrolyte and/or Fluid Balance
Hyperkalemia
Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving drugs that are associated with hyperkalemia (e.g., potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, or calcineurin inhibitors). If concomitant use cannot be avoided, closely monitor serum potassium concentrations during concomitant use [see
Hyponatremia
Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients treated concomitantly with drugs associated with hyponatremia may increase the risk of developing hyponatremia. These drugs include diuretics and those that cause SIADH (e.g., arginine vasopressin analogs, certain antiepileptic, psychotropic, or cytotoxic drugs). Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving such drugs. If use cannot be avoided, closely monitor serum sodium concentrations during concomitant use [see
Hypercalcemia
Avoid the use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients treated with thiazide diuretics or vitamin D because these drugs can increase the risk of hypercalcemia. If use cannot be avoided, closely monitor serum calcium concentrations during concomitant use [see
Hypernatremia and Fluid Retention
Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients treated concomitantly with drugs associated with sodium and fluid retention (e.g., corticosteroids or corticotropin) may increase the risk of hypernatremia and volume overload. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving such drugs. If use cannot be avoided, closely monitor serum electrolytes, fluid balance, and acid-base balance during concomitant use.
7.2 Lithium
Renal sodium and lithium clearance may be increased during concomitant use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection and lithium and may result in decreased lithium concentrations. Avoid use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection in patients receiving lithium. If use cannot be avoided, increase the frequency of monitoring of serum lithium concentrations during concomitant use.
7.3 Digoxin
Administration of calcium via use of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection may increase digoxin’s effects and lead to digoxin toxicity including serious or fatal cardiac arrhythmias. In digoxin-treated patients, consider reducing the volume and/or rate of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection administration.
7.4 Drugs with pH-Dependent Renal Elimination
Due to the alkalinizing action of lactate (formation of bicarbonate), Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection may interfere with the elimination of drugs with pH-dependent renal elimination. Renal clearance of alkaline drugs may be decreased. In contrast, renal clearance of acidic drugs may be increased.
7.5 Interference of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection with Interpretation of Serum Lactate Levels in Patients with Severe Metabolic Acidosis
Because administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection may interfere with the interpretation of serum lactate levels in patients with severe metabolic acidosis, including lactic acidosis, assessment of the patient’s clinical status should not solely rely on the measurement of serum lactate.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection as a source of water and electrolytes has been used for decades during labor and delivery. Appropriate administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with this drug.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
8.2 Lactation
Risk Summary
Lactated Ringer’s as a source of water and electrolytes and Dextrose (5%) Injection have been used for decades and is not expected to cause harm to a breastfed infant. There are no data on the presence of Lactated Ringer’s and Dextrose (5%) Injection in human milk, the effects on the breastfed infant, or the effects on milk production. Potassium is present in human breast milk. There are no data on the effects of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection on a breastfed infant or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection and any potential adverse effects on the breastfed infant from Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection or from the underlying maternal condition.
8.4 Pediatric Use
Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is contraindicated in neonates (28 days of age or younger) who are receiving ceftriaxone due to reported deaths that occurred when neonates received ceftriaxone and intravenous calcium-containing solutions concomitantly [see
The safety and effectiveness of Lactated Ringer’s Injection for use as a source of water, electrolytes, and calories or as an alkalinizing agent have been established in pediatric patients of all ages, including neonates.
The safety profile of Potassium Chloride in Dextrose Injection in pediatric patients is similar to adults.
Closely monitor plasma electrolyte concentrations in young pediatric patients with immature kidney function who may have decreased ability to maintain fluid and electrolyte balance [see
Neonates, especially preterm neonates with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions including Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to ensure adequate glycemic control to avoid potential long-term adverse reactions [see
8.5 Geriatric Use
Geriatric patients treated with Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection are at increased risk of developing electrolyte imbalances. Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is substantially excreted by the kidney, and the risk of adverse reactions to Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection may be greater in patients with renal impairment than in patients with normal renal function. Because geriatric patients are more likely to have decreased renal function, consider monitoring renal function in geriatric patients and consider starting the infusion at the low end of the dosing range.
8.6 Renal Impairment
Administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection to patients with or at risk of severe renal impairment, may result in hyperkalemia and/or fluid overload [see
8.7 Hepatic Impairment
In patients with severe hepatic impairment, lactate metabolism may be impaired, and Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection may not produce alkalinization. Closely monitor serum lactate levels and acid-base status in such patients.
10 OVERDOSAGE
Excessive administration of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection can cause:
- Hyperkalemia and hypernatremia, especially in patients with severe renal impairment.
- Fluid overload (which can lead to pulmonary and/or peripheral edema).
- Hyperglycemia, hyperosmolarity, and osmotic diuresis, dehydration, and electrolyte loss.
- Metabolic alkalosis with or without hypokalemia.
- Loss of bicarbonate with an acidifying effect.
- Hypercalcemia.
Overdose interventions include Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection discontinuation, treatment of electrolyte imbalances, treatment of hyperglycemia, and close monitoring of fluid balance, electrolyte concentrations, and acid-base balance [see
11 DESCRIPTION
Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection, USP is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. It contains no antimicrobial agents. Composition, osmolarity, pH, ionic concentration and caloric content are shown in
|
Potassium Chloride in |
Size (mL) |
Composition (g/L) |
|
pH |
Ionic Concentration (mEq/L) |
Caloric Content (kcal/L) |
||||||||
|
Dextrose, USP |
Sodium Chloride, USP |
Sodium Lactate |
Potassium Chloride, USP |
Calcium Chloride, USP |
Sodium |
Potassium |
Calcium |
Chloride |
Lactate |
|||||
|
20 mEq Potassium added |
1000 |
50 |
6 |
3.1 |
1.79 |
0.2 |
565 |
5.0 (3.5 to 6.5) |
130 |
24 |
3 |
129 |
28 |
170 |
The chemical name, structural formula, and molecular weight of the active ingredients are shown in
|
Chemical Name |
Structural Formula |
Molecular Weight |
|
Sodium Chloride, USP |
|
58.44 |
|
Sodium Lactate |
|
112.06 |
|
Potassium Chloride, USP |
|
74.55 |
|
Calcium Chloride, USP |
|
147.02 |
|
Dextrose, USP |
|
198.17 |
The VIAFLEX plastic container is fabricated from polyvinyl chloride (PL 146 Plastic). Small amounts of its chemical components (e.g., di-2-ethylhexyl phthalate [DEHP]) may leach out within the expiration period. Animal tests, USP biological tests for plastic containers, and tissue culture toxicity studies have demonstrated that the container meets safety requirements. The container is overwrapped to provide protection from the physical environment and an additional moisture barrier.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection is a source of water, electrolytes, and calories, and produces an alkalinizing effect.
- Sodium, the major cation of the extracellular fluid, functions primarily in the control of water distribution, fluid balance, and osmotic pressure of body fluids. Sodium is also associated with chloride and bicarbonate in the regulation of the acid-base equilibrium of body fluid.
- Potassium, the principal cation of intracellular fluid, participates in carbohydrate utilization and protein synthesis and is critical in the regulation of nerve conduction and muscle contraction, particularly in the heart.
- Chloride, the major extracellular anion, closely follows the metabolism of sodium, and changes in the acid-base balance of the body are reflected by changes in the chloride concentration.
- Calcium, an important cation, provides the framework of bones and teeth in the form of calcium phosphate and calcium carbonate. In the ionized form, calcium is essential for the functional mechanism of the clotting of blood, normal cardiac function, and regulation of neuromuscular irritability.
- Sodium lactate provides sodium and lactate ions. The lactate anion is in equilibrium with pyruvate and has an alkalinizing effect resulting from simultaneous removal by the liver of lactate and hydrogen ions. The sodium ion combines with bicarbonate ion produced from carbon dioxide of the body and thus retains bicarbonate to combat metabolic acidosis (bicarbonate deficiency).
- Dextrose provides a source of calories. Dextrose may decrease losses of body protein and nitrogen, promotes glycogen deposition and decreases or prevents ketosis if sufficient doses are provided.
12.2 Pharmacodynamics
The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection have not been fully characterized.
12.3 Pharmacokinetics
Elimination
Metabolism/Excretion
Potassium: Normally about 80 to 90% of the potassium intake is excreted in the urine; the remainder is excreted in feces and to a smaller extent, in perspiration.
Sodium and Chloride: The distribution and excretion of sodium (Na+) and chloride (Cl−) are largely under the control of the kidney which maintains a balance between intake and output.
Lactate: In the liver, lactate is metabolized to carbon dioxide and water by oxidative metabolism and consumption of hydrogen cations.
Dextrose: Dextrose injected parenterally undergoes oxidation to carbon dioxide and water.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity, genetic toxicology, and animal fertility studies have not been conducted with Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection.
16 HOW SUPPLIED/STORAGE AND HANDLING
How Supplied
Potassium Chloride in Lactated Ringer’s and Dextrose (5%) Injection, USP is supplied as a clear solution in single-dose VIAFLEX plastic containers as follows:
|
Code |
Size (mL) |
NDC |
Product Name |
|
2B2224 |
1000 |
0338-0811-04 |
20 mEq/L Potassium Chloride in Lactated Ringer’s and 5% Dextrose Injection, USP |
Storage and Handling
Store at room temperature (recommended 25°C/77°F).
Brief exposure up to 40°C (104°F) does not adversely affect the product. Exposure to heat should be minimized. Avoid excessive heat.
Baxter Healthcare Corporation
Deerfield, IL 60015 USA
Baxter, PL 146 and Viaflex are trademarks of Baxter International Inc. or its subsidiaries.
07-19-00-9427
PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
Container Label
LOT
EXP
2B2224
NDC 0338-0811-04
DIN 00786314
20 mEq
Potassium Chloride
(20 mEq/L) Potassium Chloride in
Lactated Ringer's and 5% Dextrose
Injection USP
1000 mL
EACH 100 mL CONTAINS 5 g DEXTROSE HYDROUS USP 600 mg
SODIUM CHLORIDE USP 310 mg SODIUM LACTATE 179 mg
POTASSIUM CHLORIDE USP 20 mg CALCIUM CHLORIDE USP pH
5.0 (3.5 TO 6.5) mEq/L SODIUM 130 POTASSIUM 24
CALCIUM 3 CHLORIDE 129 LACTATE 28 HYPERTONIC
OSMOLARITY 565 mOsmol/L (CALC) STERILE NONPYROGENIC
SINGLE DOSE CONTAINER NOT FOR USE IN THE TREATMENT OF
LACTIC ACIDOSIS ADDITIVES MAY BE INCOMPATIBLE CONSULT WITH
PHARMACIST IF AVAILABLE WHEN INTRODUCING ADDITIVES USE
ASEPTIC TECHNIQUE MIX THOROUGHLY DO NOT STORE DOSAGE
INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN SEE DIRECTIONS
CAUTIONS SQUEEZE AND INSPECT INNER BAG WHICH MAINTAINS
PRODUCT STERILITY DISCARD IF LEAKS ARE FOUND MUST NOT BE
USED IN SERIES CONNECTIONS DO NOT ADMINISTER
SIMULTANEOUSLY WITH BLOOD DO NOT USE UNLESS SOLUTION IS
CLEAR Rx ONLY STORE UNIT IN MOISTURE BARRIER OVERWRAP AT
ROOM TEMPERATURE (25°C/77°F) UNTIL READY TO USE AVOID
EXCESSIVE HEAT SEE INSERT
VIAFLEX PLUS CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
FOR PRODUCT INFORMATION 1-800-933-0303
Baxter
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
DISTRIBUTED IN CANADA BY
BAXTER CORPORATION
TORONTO ONTARIO CANADA